Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W-135 and Y conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent meningococcal conjugate vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, C, W-135 (W), and Y. The polysaccharides from each serogroup are individually purified and chemically linked (conjugated) to a carrier protein such as diphtheria toxoid or tetanus toxoid. This enhances the immune response compared to unconjugated polysaccharide vaccines by inducing T-cell dependent immunity. The primary indication is prevention of invasive meningococcal disease in children (as young as 2 months for some brands), adolescents, and adults up to 55 years of age[1][2][3][4][5][7]. It does not protect against serogroup B.
- Brand names
- MenveoMenQuadfiMenactraNimenrix
- Other names
- MenACWY vaccinemeningococcal conjugate vaccine (groups A, C, W-135 and Y)quadrivalent meningococcal conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A, C, W-135 and Y conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W-135 and Y conjugate vaccine.